Profile data is unavailable for this security.
About the company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
- Revenue in CHF (TTM)62.80bn
- Net income in CHF13.93bn
- Incorporated1966
- Employees100.92k
- LocationRoche Holding AGGrenzacherstr. 124BASEL 4058SwitzerlandCHE
- Phone+41 9 732354295
- Websitehttp://www.roche.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer AG | 47.66bn | 2.26bn | 64.37bn | 100.75k | 28.45 | 1.67 | 11.88 | 1.35 | 2.24 | 2.24 | 47.22 | 38.11 | 0.3798 | 1.62 | 3.37 | 465,610.20 | 1.82 | -1.37 | 2.42 | -1.77 | 62.72 | 59.99 | 4.80 | -3.73 | 0.8826 | 7.25 | 0.5308 | -- | 6.48 | 4.76 | 106.42 | -23.20 | 0.2547 | -5.52 |
| Novartis AG | 50.96bn | 23.25bn | 211.38bn | 110.00k | 8.52 | 3.29 | 7.25 | 4.15 | 10.32 | 10.32 | 22.67 | 26.74 | 0.4292 | 2.19 | 6.36 | 488,450.40 | 19.58 | 9.08 | 25.89 | 11.56 | 71.02 | 70.62 | 45.62 | 24.73 | 1.01 | -- | 0.3364 | 58.80 | 5.97 | 1.38 | 197.58 | 29.05 | 0.6311 | 3.44 |
| Roche Holding AG | 62.80bn | 13.93bn | 274.63bn | 100.92k | 20.57 | 10.88 | 14.17 | 4.37 | 16.19 | 16.19 | 73.02 | 30.60 | 0.7038 | 2.60 | 5.99 | 622,285.00 | 16.74 | 15.62 | 27.82 | 23.77 | 69.19 | 71.04 | 23.78 | 21.82 | 0.7266 | 27.46 | 0.524 | 62.04 | 7.68 | 4.42 | -2.55 | 7.78 | -1.99 | 2.55 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 May 2022 | 19.39m | 2.76% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 18.01m | 2.56% |
| BlackRock Fund Advisorsas of 04 May 2022 | 11.99m | 1.71% |
| UBS Asset Management Switzerland AGas of 03 May 2022 | 11.75m | 1.67% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2022 | 11.12m | 1.58% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Apr 2022 | 9.03m | 1.29% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Jan 2022 | 6.83m | 0.97% |
| BlackRock Advisors (UK) Ltd.as of 04 May 2022 | 5.79m | 0.82% |
| Massachusetts Financial Services Co.as of 30 Apr 2022 | 5.20m | 0.74% |
| Alecta Pension Insurance Mutualas of 31 Dec 2019 | 5.09m | 0.73% |
